A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...

Among patients who were newly diagnosed with multiple myeloma, Kyprolis (carfilzomib) plus Revlimid (lenalidomide) and dexamethasone (KRd) was associated with improvements in progression-free survival ...

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ...

Elrexfio showed higher response rates but shorter PFS compared to Tecvayli in real-world settings for relapsed/refractory ...

Nearly 30% of families with children undergoing ALL treatment face catastrophic financial toxicity, including household ...

From left: Oya Gilbert, Bill Potts, Dr. Faseeh Khaja's nominator, Mayra, and Joe McDonough at the first annual Blood Cancer ...

One of biggest stories or developments in acute myeloid leukemia or AML is the wider adoption and use of the regimen of ...

The narrative challenges the idea that extended survival equates to sufficient time, emphasizing the profound loss of a young ...